104 terminated. 104 Phase 2, 15 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 104 | Terminated 104 |
| Phase 1 | 15 | Terminated 15 |
| Phase 3 | 4 | Terminated 4 |
Follow Bronchial Diseases: new trials by email Literature Review of Bronchial Diseases trials Research Report on Bronchial Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant Echocardiography Test, Ibrutinib - Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Terminated | Mayo Clinic | 2 | 2024-12-13 | 2026-05-22 |
| A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma Rocatinlimab, Placebo - Asthma | Phase 2 | Terminated | Amgen | 317 | 2024-05-24 | 2026-08-11 |
| Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo - Uncontrolled Asthma | Phase 2 | Terminated | Chiesi Farmaceutici S.p.A. | 517 | 2023-11-26 | 2025-12-18 |
| Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant Leflunomide tablet - Musculoskeletal Disease Other, GVHD, Chronic | Phase 2 | Terminated | Tata Memorial Centre | 1 | 2023-09-18 | 2025-09-10 |
| Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Amlitelimab, Placebo - Asthma | Phase 2 | Terminated | Sanofi | 335 | 2023-09-05 | 2026-10-02 |
| Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma RPT193, Placebo - Asthma | Phase 2 | Terminated | RAPT Therapeutics, Inc., a member of the GSK plc group of companies | 38 | 2023-07-05 | 2026-03-23 |
| Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias fostamatinib - Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 1 | 2023-03-10 | 2025-12-05 |
| Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA Itraconazole Powder, Placebo - ABPA | Phase 2 | Terminated | Pulmatrix Inc. | 8 | 2023-02-01 | 2024-04-02 |
| Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease ARO-MUC5AC, Placebo - Asthma, Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Terminated | Arrowhead Pharmaceuticals | 78 | 2022-06-27 | 2026-09-14 |
| A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma AK120, Placebo - Asthma | Phase 2 | Terminated | Akeso | 1 | 2022-02-11 | 2022-10-12 |
| Ruxolitinib for Early Lung Dysfunction After Hematopoietic Stem Cell Transplant Ruxolitinib - Hematopoietic Stem Cell Transplant (HSCT), Bronchiolitis Obliterans (BO) | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 7 | 2021-11-12 | 2026-04-07 |
| Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma CSJ117, Placebo - Asthma | Phase 2 | Terminated | Novartis Pharmaceuticals | 136 | 2021-09-08 | 2022-10-10 |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Alectinib - Neoplasms, Colorectal Neoplasms | Phase 2 | Terminated | Hoffmann-La Roche | 1 | 2021-05-24 | 2023-08-07 |
| A Study to Test if TEV-53275 is Effective in Relieving Asthma TEV-53275 Dose A, TEV-53275 Dose B, Placebo - Asthma | Phase 2 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 97 | 2021-05-04 | 2023-06-08 |
| Efficacy and Safety of Inhaled AZD1402 Administered for Four Weeks in Adults With Asthma on Medium-to-High Dose Inhaled Corticosteroids AZD1402, Placebo, Short acting beta agonist (SABA) (rescue medication) - Asthma | Phase 2 | Terminated | AstraZeneca | 72 | 2021-03-12 | 2025-08-28 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib itacitinib - Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans) | Phase 2 | Terminated | Incyte Corporation | 18 | 2021-03-10 | 2026-06-26 |
| COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2 RESP301 - COPD, Bronchiectasis | Phase 2 | Terminated | Thirty Respiratory Limited | 88 | 2021-03-01 | 2025-01-31 |
| Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QBW251 in Subjects With Bronchiectasis QBW251, Placebo - Bronchiectasis | Phase 2 | Terminated | Novartis Pharmaceuticals | 42 | 2021-02-02 | 2025-09-26 |
| Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Itacitinib, Extracorporeal Photopheresis (ECP) - Chronic Graft-versus-host-disease | Phase 2 | Terminated | University of Utah | 3 | 2021-01-29 | 2024-01-22 |
| A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB) ION-827359, Placebo - Chronic Bronchitis, Chronic Obstructive Pulmonary Disease | Phase 2 | Terminated | Ionis Pharmaceuticals, Inc. | 60 | 2020-12-22 | 2022-12-20 |
Showing 20 of 104. Sign in to see all of them.
Asthma (57) · Bronchiolitis Obliterans Syndrome (32) · Pulmonary Disease, Chronic Obstructive (7) · Bronchiolitis Obliterans (6) · Bronchiectasis (5) · Graft vs Host Disease (5) · Bronchial Neoplasms (3) · Bronchiolitis (3) · Respiratory Sounds (3) · Status Asthmaticus (3) · Breast Neoplasms (2) · Bronchitis, Chronic (2) · Carcinoma, Bronchogenic (2) · Hypersensitivity (2) · Leukemia (2)
Respiratory Tract Diseases (103) · Lung Diseases (100) · Lung Diseases, Obstructive (99) · Immune System Diseases (89) · Hypersensitivity, Immediate (57) · Respiratory Hypersensitivity (57) · Hypersensitivity (55) · Bronchitis (41) · Bronchiolitis (36) · Organizing Pneumonia (33) · Bronchiolitis Obliterans (30) · Graft vs Host Disease (27) · Pathological Conditions, Signs and Symptoms (17) · Pathologic Processes (12)
Fluticasone (5) · itacitinib (5) · Azithromycin (4) · INCB039110 (4) · Epinephrine (3) · Rituximab (3) · ibrutinib (3) · Lenalidomide (2) · Prednisone (2) · Sirolimus (2) · enokizumab (2) · ligelizumab (2) · montelukast (2) · 3-(2-(4-azidobenzamidino)ethyl)-5-hydroxyindole (1) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1)
Novartis Pharmaceuticals (11) · Boehringer Ingelheim (3) · Incyte Corporation (3) · M.D. Anderson Cancer Center (3) · MedImmune LLC (3) · Amgen (2) · Amphastar Pharmaceuticals, Inc. (2) · Children's Hospital Medical Center, Cincinnati (2) · Dana-Farber Cancer Institute (2) · GlaxoSmithKline (2) · Johns Hopkins University (2) · Laboratorios Leti, S.L. (2) · Merck Sharp & Dohme LLC (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · University of Utah (2)
United States (64) · Canada (22) · Germany (21) · United Kingdom (19) · Poland (16) · Spain (13) · France (11) · Belgium (9) · Hungary (9) · South Korea (9) · Argentina (8) · Czechia (8) · Italy (8) · Russia (7) · Australia (6)
Joseph Parker, M.D. (2) · Adam Hill, MD PhD (1) · Alessio Fasano, M. D. (1) · Amin Alousi, MD (1) · Anne E Dixon, MD (1) · Antonio Nieto, MD PhD (1) · Catherine Lee, MD (1) · Chris Cabell, MD (1) · Christina D Adams, PhD (1)
PMID 21356110, PMID 21945511, PMID 23900970, PMID 23949578, PMID 24995515, PMID 25389139, PMID 26416925, PMID 27207315, PMID 32150492, PMID 32840597, PMID 33032168, PMID 33314326, PMID 34265047, PMID 34326185, PMID 35781099, PMID 36735745, PMID 37698881, PMID 38485149, PMID 39393433, PMID 40311075
2018 (3), 2019 (3), 2008 (2), 2015 (2), 2009 (1), 2014 (1), 2017 (1), 2023 (1), P01AT002647 (1), P30CA042014 (1), R21AT004089 (1), U01HL119952 (1)